NVAXNovavax, Inc.

NVAX Stock Price, Valuation & Chart | Novavax, Inc.

Compare

$10.120+0.75 (+8.00%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NVAX intrinsic value NVAX calculated fair value vs price

Overview Financials Dividends Ratios

NVAX Historical price chart

NVAX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.66B

PE Ratio-6.66

EPS-1.52

Trading Volume10.02M

Today's High/Low10.26/9.19

Dividend Yield0.00

52 Week High/Low11.97/6.2

Shares Outstanding164.44M

NVAX Financial Statement

NVAX Analyst ratings

NVAX Analysis & performance metrics

NVAX Company profile

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health…

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent…

NVAX Management team

Name

Position

Richard P. CrowleyCOO

Executive Vice President & Chief Operating Officer

Troy Morgan Esq., J.D.

Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Silvia Taylor M.B.A.

Executive Vice President and Chief Corporate Affairs & Advocacy Officer

Henrietta Ukwu FACP FRAPS, M.D.

Executive Vice President & Chief Regulatory Officer

Elaine O'Hara

Executive Vice President & Chief Strategy Officer

John Charles Jacobs M.B.A.CEO

President, Chief Executive Officer & Director

Erika S. TrahanCTO

Associate Director of Investor & Public Relations

John Joseph Trizzino B.S., M.B.A.COO

President & Chief Operating Officer

Name

Position

Richard P. CrowleyCOO

Executive Vice President & Chief Operating Officer

Troy Morgan Esq., J.D.

Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Silvia Taylor M.B.A.

Executive Vice President and Chief Corporate Affairs & Advocacy Officer

Henrietta Ukwu FACP FRAPS, M.D.

Executive Vice President & Chief Regulatory Officer

Elaine O'Hara

Executive Vice President & Chief Strategy Officer

John Charles Jacobs M.B.A.CEO

President, Chief Executive Officer & Director

Erika S. TrahanCTO

Associate Director of Investor & Public Relations

John Joseph Trizzino B.S., M.B.A.COO

President & Chief Operating Officer

Management Team

Richard P. CrowleyCOO

Executive Vice President & Chief Operating Officer

Troy Morgan Esq., J.D.

Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Silvia Taylor M.B.A.

Executive Vice President and Chief Corporate Affairs & Advocacy Officer

Henrietta Ukwu FACP FRAPS, M.D.

Executive Vice President & Chief Regulatory Officer

Elaine O'Hara

Executive Vice President & Chief Strategy Officer

John Charles Jacobs M.B.A.CEO

President, Chief Executive Officer & Director

Erika S. TrahanCTO

Associate Director of Investor & Public Relations

John Joseph Trizzino B.S., M.B.A.COO

President & Chief Operating Officer

Management

Richard P. CrowleyCOO

Executive Vice President & Chief Operating Officer

Troy Morgan Esq., J.D.

Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Silvia Taylor M.B.A.

Executive Vice President and Chief Corporate Affairs & Advocacy Officer

Henrietta Ukwu FACP FRAPS, M.D.

Executive Vice President & Chief Regulatory Officer

Elaine O'Hara

Executive Vice President & Chief Strategy Officer

John Charles Jacobs M.B.A.CEO

President, Chief Executive Officer & Director

Erika S. TrahanCTO

Associate Director of Investor & Public Relations

John Joseph Trizzino B.S., M.B.A.COO

President & Chief Operating Officer

Total 8 executives

NVAX Frequently asked questions

What is Novavax, Inc. (NVAX) Stock Price?

Current stock price of Novavax, Inc. (NVAX) stock is $10.120. The stock price is +8.00% higher in the session. The intraday range can be seen from this page. Volume of Novavax, Inc. (NVAX) stock is 10.02M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Novavax, Inc. (NVAX) stock price going up or down today?

The stock price of Novavax, Inc. (NVAX) can change with earnings, company news, and overall market sentiment. Novavax, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Novavax, Inc. stock expensive at its current price?

Whether Novavax, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NVAX on this page is -6.66. EPS on this page is -1.52. Compare those figures with peers and growth expectations before deciding if the current Novavax, Inc. price is justified.

How has the stock price of Novavax, Inc. (NVAX) performed historically?

Historical performance for Novavax, Inc. (NVAX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NVAX reacted to past earnings and market events.

Should I buy Novavax, Inc. (NVAX) stock, at this price?

Buying Novavax, Inc. (NVAX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.